with an unrestricted educational grant of
cGVHD part I
F. Ciceri (Milano), M. Martino (Reggio Calabria)
ECP in the era of new drugs for cGVHD: which role and which schedule?
H. Greinix (Graz, AT)Non immune effector targets in cGVHD
A. Olivieri (Ancona)What to do in ruxolitinib-refractory cGVHD?
D. Wolff (Regensburg, DE)Overlap cGVHD: assessment in the real life and proposal of a prospective GITMO study
D. Pulanic (Zagreb, HR)Overlap cGVHD: assessment in the real life and proposal of a prospective GITMO study
J. Mariotti (Milano)cGVHD part II: burning topics in lung cGVHD
Chairmen: A. Bacigalupo (Genova), G. Moroncini (Ancona)